Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Phase 2
18+
1 site in CA
What this study is about
This Phase 2 study is testing Soquelitinib in people with atopic dermatitis. The primary outcome being measured is Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
kinase inhibitor
Primary: Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
Secondary: Response of achieving ≥4-point decrease in Peak Pruritus-Numerical Rating Scale (PP-NRS) score at Week 12, Safety and tolerability
Dermatology